BioCryst Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of BioCryst Pharmaceuticals generated cash of -$95,141,000, which is more than the previous year. Cash used in financing activities reached the amount of $32,485,000 last year. Net change in cash is therefore -$193,792,000.
Cash Flow
| 2014 | -38.55M | -39.98M | 111.90M |
|---|---|---|---|
| 2015 | -13.11M | -18.00M | 5.47M |
| 2016 | -53.43M | 23.33M | 23.30M |
| 2017 | -41.14M | -66.38M | 135.70M |
| 2018 | -92.56M | 4.76M | 62.50M |
| 2019 | -89.58M | 77.93M | 99.09M |
| 2020 | -137.21M | -6.85M | 302.69M |
| 2021 | -142.15M | 15.80M | 359.66M |
| 2022 | -161.85M | -128.23M | 88.02M |
| 2023 | -95.14M | -131.49M | 32.48M |
BCRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 306.23M | 507.73M | 274.34M | 115.72M | 28.27M | 53.56M | 22.10M | 28.89M | 54.54M | 21.16M |
Operating activities | ||||||||||
Net income | -226.53M | -247.11M | -184.06M | -182.81M | -108.89M | -101.25M | -65.78M | -55.14M | -43.01M | -45.18M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.65M | 1.43M | 777K | 748K | 724K | 770K | 704K | 483K | 180K | 177K |
Stock-based compensation expense | 55.61M | 44.70M | 34.64M | 14.79M | 17.71M | 0 | 12.62M | 8.48M | 9.70M | 10.17M |
| Deferred income tax benefit | 55.61M | 44.70M | 34.64M | 14.79M | 17.71M | 0 | 12.62M | 8.48M | 9.70M | 10.17M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -6.09M | -21.47M | -23.80M | 18.52M | -16.16M | 568K | 2.65M | -2.52M | -7.37M | -7.37M |
Inventories | -1.45M | -12.42M | -8.76M | -7.03M | 1.64M | -1.64M | 500K | 1.11M | -929K | -683K |
Accounts payable | -16.80M | -22.36M | 39.41M | 17.35M | 11.74M | 4.48M | 3.84M | -10.52M | 6.81M | 6.81M |
Cash generated by operating activities | -95.14M | -161.85M | -142.15M | -137.21M | -89.58M | -92.56M | -41.14M | -53.43M | -13.11M | -38.55M |
Investing activities | ||||||||||
Purchases Of Investments | -514.40M | -244.28M | -10.01M | -49.81M | -3.01M | -62.61M | -107.78M | -14.10M | -53.83M | -73.87M |
Investments In Property Plant And Equipment | -2.16M | -1.35M | -2.38M | -514K | -343K | -366K | -328K | -5.27M | -5.12M | -106K |
Acquisitions Net | 0 | 1.35M | 2.38M | 513K | 366K | 366K | 12K | 4K | 0 | 0 |
Cash generated by investing activities | -131.49M | -128.23M | 15.80M | -6.85M | 77.93M | 4.76M | -66.38M | 23.33M | -18.00M | -39.98M |
Financing activities | ||||||||||
Common Stock Issued | 342K | 14.95M | 50M | 93.27M | 58.5M | 53.4M | 134M | 317K | 5.47M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 27.14M | 73.07M | -293.87M | -52.42M | 19.47M | -4.02M | 122K | 0 | 0 | 0 |
Cash used in financing activities | 32.48M | 88.02M | 359.66M | 302.69M | 99.09M | 62.50M | 135.70M | 23.30M | 5.47M | 111.90M |
Net Change In Cash | -193.79M | -201.49M | 233.38M | 158.62M | 87.44M | -25.29M | 28.17M | -6.79M | -25.64M | 33.37M |
Cash at end of period | 112.44M | 306.23M | 507.73M | 274.34M | 115.72M | 28.27M | 50.28M | 22.10M | 28.89M | 54.54M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |